SCHEMBL7354022

SCHEMBL7354022

CCCN(CC)c1cc(C)nc(Sc2c(C)cc(C)cc2C)c1C

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 20/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5844224 0.74 CRHR1 (0.51) CRHR1
SCHEMBL5844604 0.70 CRHR1 (0.36) CRHR1
SCHEMBL5843299 0.69 LMNA (0.35) CRHR1
SCHEMBL5844622 0.68 CRHR1 (0.46) CRHR1
SCHEMBL5788008 0.67 CRHR1 (0.55) CRHR1
SCHEMBL5844606 0.67 TAAR1 (0.37)
SCHEMBL5843248 0.67 CRHR1 (0.53) CRHR1
SCHEMBL5844633 0.67 CRHR1 (0.49) CRHR1
SCHEMBL5843292 0.67 CRHR1 (0.59) CRHR1
SCHEMBL5844779 0.67 CRHR1 (0.57) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6387894-B1 MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS PFIZER INC. 2002-05-14 US claimed
US-6384039-B1 ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST PFIZER INC. 2002-05-07 US claimed
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CHEN YUHPYNG L (US) 2001-04-19 US claimed
EP-1059100-A2 Combinations of CRF antagonists and renin-angiotensin system inhibitors Pfizer Products Inc. (US) 2000-12-13 EP claimed
EP-1040831-A2 Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death Pfizer Products Inc. (US) 2000-10-04 EP claimed
US-6387894-B1 MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS PFIZER INC. 2002-05-14 US disclosed
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CHEN YUHPYNG L (US) 2001-04-19 US disclosed
EP-1059100-A2 Combinations of CRF antagonists and renin-angiotensin system inhibitors Pfizer Products Inc. (US) 2000-12-13 EP disclosed
US-5962479-A Corticotropin releasing factor antagonists PFIZER INC. (US) 1999-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CRH, CRHR1, CRHR2 CRHR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.